The takeaway
Zevra Therapeutics Inc. shows a moderate seasonal pattern over 10 years of data — strongest in May (−4.1%) and softest in October (−7.2%).
Right now
In July, the stock has risen 40% of years, averaging +2.2% — essentially in line with the S&P 500.
The full picture
Zevra Therapeutics Inc.'s most dependable month has been May, higher in 7 of 10 years; October has been its least reliable, up just 40% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in August (+5.4 pts); it has trailed the market most in October (−8.2 pts).
“vs S&P” is Zevra Therapeutics Inc.’s average for a month minus the S&P 500’s average for that same month — isolating Zevra Therapeutics Inc.’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, May has closed higher 80% of the time versus 70% across the last 10 years — the pattern is strengthening.
Figures are the typical (median) May return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: May, up in 7 of 10 Mays while the other eleven tend to blur together.
Its average (−4.1%) and median (+1.1%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even May ranges by 24.1% from year to year, so any single year can land far from the average. That consistency sets it apart from the field, where the average stock manages May only about 55% of the time.
A few other months pull their weight: February and August have also closed higher more often than not. The weaker half of the year is plainer: October has been the soft spot — the weakest of 7 months that average a loss (−7.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in October, December, and March.
If anything it has sharpened recently — the last five Mays run ahead of the earlier years.
The takeaway is less about when to buy than what to expect: May aside, the stock's months offer little reliable tilt. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (May), its worst (October), and whether it really trades seasonally.
Yes, to a moderate degree. Since 2016 its best month (May, −4.1%) has run well ahead of its worst (October, −7.2%) — the heatmap above shows how steady that gap has been year to year.
May has been the strongest, averaging −4.1% and closing higher in 7 of 10 years since 2016.
It's the weakest, averaging −7.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade